Yesterday it was reported that a Director at Pacira Pharmaceuticals (PCRX), Gary Pace, exercised options to buy 21,736 PCRX shares at $4.45 a share, for a total transaction value of $96.84K.
This recent transaction increases Gary Pace’s holding in the company by 109.41% to a total of $2.06 million. In addition to Gary Pace, 2 other PCRX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $122 million and GAAP net loss of $4.89 million. In comparison, last year the company earned revenue of $95.12 million and had a net profit of $8.29 million. The company has a one-year high of $51.35 and a one-year low of $29.42. Currently, Pacira Pharmaceuticals has an average volume of 635.80K.
Seven different firms, including Barclays and Needham, currently also have a Buy rating on the stock. Starting in February 2020, PCRX received 4 Buy ratings in a row.
The insider sentiment on Pacira Pharmaceuticals has been positive according to 50 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Gary Pace’s trades have generated a 4.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
